Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:8
  • preuzimanja u poslednjih 30 dana:7
članak: 3 od 13  
Back povratak na rezultate
Medicinski pregled
2013, vol. 66, br. 5-6, str. 209-213
jezik rada: srpski
vrsta rada: izvorni naučni članak
objavljeno: 11/07/2013
doi: 10.2298/MPNS1306209D
Ishod lečenja enterokolitisa koji izaziva Clostridium difficile primenom antibiotika uz probiotik
aKlinički centar Vojvodine, Klinika za infektivne bolesti, Novi Sad
bUniverzitet u Novom Sadu, Poljoprivredni fakultet, Departman za veterinarsku medicinu

Projekat

Unapređenje i razvoj higijenskih i tehnoloških postupaka u proizvodnji namirnica životinjskog porekla u cilju dobijanja kvalitetnih i bezbednih proizvoda konkurentnih na svetskom tržištu (MPNTR - 46009)

Sažetak

Uvod. Enterokolitis koji izaziva Clostridium difficile je potencijalno fatalna bolest sa porastom incidencije u bolničkim uslovima. Terapijski pristup u lečenju enterokolitisa predstavlja značajan problem zbog skolnosti ka relapsu i reinfekciji. Cilj rada bio je ispitivanje faktora koji utiču na pojavu enterokolitisa koji izaziva Clostridium difficile i ishoda enetrokolitisa nakon primene standardne antimikrobne terapije u kombinaciji sa probiotikom. Materijal i metode. Sprovedeno je nekomparativno, opservaciono, prospektivno ispitivanje na 42 bolesnika (22 muškarca i 20 žena) koji su lečeni na Klinici za infektivne bolesti u Novom Sadu u periodu od oktobra 2011. do aprila 2012. godine pod dijagnozom enterokolitisa koji je izazvao Clostridium difficile. Rezultati. Nastanak bolesti bio je češći kod starijih bolesnika (78,6% bilo je starije od 60 godina), kod prethodne upotrebe antimikrobne terapije (83,8%), prethodne hospitalizacije (83,3%) i komorbiditeta (85,7%). Kliničkom slikom su dominirale blaže do umerene tegobe. Na primenjenu standardnu antibiotsku terapiju (metronidazol, vankomicin) uz probiotik tokom 10 dana, broj i izgled stolica, osećaj bola u trbuhu i osećaj nadutosti pokazali su signifikantno povoljan klinički odgovor. Statistički značajne promene u laboratorijskim parametrima (broj leukocita, Creaktivni protein) zabeležene su 5. dana bolesti. Rekurentna infekcija, nakon uspešno spovedene terapije, registrovana je kod 9,5% bolesnika. Zaključak. Primena probiotskih bakterija Lactobacillus acidophilus Rosell-52, Lactobacillus rhamnosus Rosell-11 i Bifidobacterium longum Rosell-175 u kombinaciji sa standardnom antibiotskom terapijom kod bolesnika sa entrokolitisom izazvanim Clostridium-om difficile imala je povoljan učinak na težinu kliničke slike i normalizaciju laboratorijskih parametara. Rekurentna infekcija nakon uspešno spovedene terapije zabeležena je kod manjeg broja bolesnika nego što se navodi u literaturi.

Ključne reči

Reference

Aberra, F.N. (2012) Clostridium difficile colitis. Medscape, May, http://emedicine.medscape.com/article/186458-overview
Allen, S.J., Wareham, K., Bradley, C., Harris, W., Dhar, A., Brown, H., Foden, A., Cheung, W., Gravenor, M.B., Plummer, S., Phillips, C.J., Mack, D. (2012) A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. BMC Infectious Diseases, 12(1): 108
Al‐Nassir, Wafa N., Sethi, Ajay K., Nerandzic, Michelle M., Bobulsky, Greg S., Jump, Robin L. P., Donskey, Curtis J. (2008) Comparison of Clinical and Microbiological Response to Treatment of Clostridium difficile -Associated Disease with Metronidazole and Vancomycin. Clinical Infectious Diseases, 47(1): 56-62
Bauer, M.P., Kuijper, E.J., van Dissel, J.T. (2009) European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clinical Microbiology and Infection, 15(12): 1067-1079
Boskovic, K.M., Todorovic-Tomasevic, S., Zvekic-Svorcan, J.S., Simic, D.S., Knezevic, A.L. (2012) General Health Related Quality of Life in Patients with Osteoporosis. Osteoporosis International, vol. 23, br. 2, str. S189-S189
Bouza, E., Burillo, A., Muñoz, P. (2006) Antimicrobial Therapy of Clostridium difficile-Associated Diarrhea. Medical Clinics of North America, 90(6): 1141-1163
Cohen, Stuart H., Gerding, Dale N., Johnson, S., Kelly, Ciaran P., Loo, Vivian G., McDonald, C.L., Pepin, J., Wilcox, Mark H. (2010) Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology, 31(5): 431-455
Davidson, L.E., Hibberd, P.L. (2011) Clostridium difficile and probiotics. http://www.uptodate.com/contents/clostridium-difficile-and-probiotics
Dumyati, G., Stevens, V., Hannett, G.E., Thompson, A.D., Long, C., MacCannell, D., Limbago, B. (2012) Community-associated Clostridium difficile Infections, Monroe County, New York, USA. Emerging Infectious Diseases, 18(3): 392-400
Fedorak, R.N., Madsen, K.L. (2004) Probiotics and prebiotics in gastrointestinal disorders. Current Opinion in Gastroenterology, 20(2): 146-155
Gao, X.W., Mubasher, M., Fang, C.Y., Reifer, C., Miller, L.E. (2010) Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. American journal of gastroenterology, 105(7): 1636-41
Goldin, B. R., Gorbach, S. L. (2008) Clinical Indications for Probiotics: An Overview. Clinical Infectious Diseases, 46(s2): S96-S100
Hempel, S., Newberry, S.J., Maher, A.R., Wang, Z., Miles, J.N.V., Shanman, R., Johnsen, B., Shekelle, P.G. (2012) Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA, 307(18): 1959-69
Hickson, M. (2011) Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therapeutic Advances in Gastroenterology, 4(3): 185-197
Hulisz, D. (2011) Probiotics for antibiotic-associated diarrhea. Medscape, July, http://www.medscape.com/viewarticle/746534
Kale-Pradhan, P.B., Jassal, H.K., Wilhelm, S.M. (2010) Role of Lactobacillus in the Prevention of Antibiotic-Associated Diarrhea: A Meta-analysis. Pharmacotherapy, 30(2): 119-126
Keller, D.M. (2010) Some clostridium difficile infections associated with previous antibiotic use. u: Medscape Medical News: Infectious Diseases Society of America (IDSA), 48th Annual Meeting, Abstract 450, http://www.medscape.com/viewarticle/731213
Kelly, C.P., Pothoulakis, C., LaMont, J.T. (1994) Clostridium difficile colitis. New England journal of medicine, 330(4): 257-62
Lang, F.C. (2010) Use of a multi-species probiotic. Nutrafoods, 9(2): 27-31
Leffler, D.A., Lamont, T.J. (2009) Treatment of Clostridium difficile-Associated Disease. Gastroenterology, 136(6): 1899-1912
Mcfarland, L.V. (2009) Evidence-based review of probiotics for antibiotic-associated diarrhea and clostridium difficile infections. Anaerobe, 15, str. 274-280
Musher, D.M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., Hamill, R.J. (2005) Relatively Poor Outcome after Treatment of Clostridium difficile Colitis with Metronidazole. Clinical Infectious Diseases, 40(11): 1586-1590
Plummer, S., Weaver, M.A., Harris, J.C., Dee, P., Hunter, J. (2004) Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. International microbiology, 7(1): 59-62
Pollak, L. (2008) Dodaci prehrani i hrana za posebne prehrambene potrebe. Medicus, 17(1): 47-55
Stefan-Mikic, S., Sevic, S., Doder, R.Z., Cvjetkovic, D., Jovanovic, N., Ruzic, M. (2011) Implementation influence of antibiotic prescribing guidelines on their usage and costs of therapy. HEALTHMED, vol. 5, br. 6, str. 1710-1718
Vuković, M. (2001) Bacillus subtilis IP 5832 (Flonivin BS) skraćuje period kliconoštva kod bolesnika sa akutnim netifoidnim salmoneloznim enteritisom. Medicinski pregled, vol. 54, br. 1-2, str. 62-68
Yan, F., Polk, D.B. (2010) Probiotics: progress toward novel therapies for intestinal diseases. Current Opinion in Gastroenterology, 26(2): 95-101